

Doc No.: 12810-00142-US (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Lacour et al.	Conf. No.: 7204
Application No.: 10/519210	Group Art Unit: Not Yet Assigned
Filed: December 23, 2004	Examiner: Not Yet Assigned
For: PLASMID VECTORS FOR TRANSFORMATION OF FILAMENTOUS FUNGI	

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§1.821 THROUGH 1.825

MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

\boxtimes	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the information recorded in computer readable form is identical to the written Sequence Listing submitted herewith.
\boxtimes	I hereby state that the submission filed in accordance with 37 C.F.R. 1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, in pages 1 of the Sequence Listing. I hereby state that the substitute sheets of the Sequence Listing do not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.

416494

Doc. No.: 12810-00142-US (PATENT)

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed on .

Respectfully submitted,

Roberte M. D. Makowski

Registration No.: 55,421

CONNOLLY BOVE LODGE & HUTZ LLP

1007 North Orange Street

P.O. Box 2207


Wilmington, Delaware 19899

(302) 658-9141

(302) 658-5614 (Fax)

Attorney for Applicants

416494 2



JNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE . United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FIRST NAMED APPLICANT ATTY. DOCKET NO. 53262-20100.00 Thierry Lacour 10/519.210

INTERNATIONAL APPLICATION NO.

I.A. FILING DATE

07/02/2003

PCT/EP03/07028

25227 MORRISON & FOERSTER LLP 1650 TYSONS BOULEVARD DOCKETER SUITE 300 MCLEAN, VA 22102

REMINDER

CONFIRMATION NO. 7204

PRIORITY DATE

07/05/2002

371 FORMALITIES LETTER OC000000016392886*

DUE DATE: FINAL DUE DATE:

Date Mailed: 07/01/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any commications to the United States Patent and Transhark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.				
10/519,210	PCT/EP03/07028	53262-20100.00				

FORM PCT/DO/EO/922 (371 Formalities Notice)





PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/519210

Attorney Docket No.: 12810-00142-US

Certificate of Mailing under 37 CFR 1.8

Thereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

> MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

September 21, 2005 Date

Signature

Tina R. Hall Typed or printed name of person signing Certificate

Registration Number, if applicable

(302) 658-9141 Telephone Number

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Response to Notice to Comply with Requirements for Patent Application Containing Nucleotide and/or Amino Acid Sequence Disclosures (3 pages)

Statement to Support Filing and Submission in Accordance with 37 CFR 1.821 - 1.825 (2 pages)

Sequence Listing (67 pages)

Diskette containing Sequence Listing

Copy of Notification to Comply With Requirements for Patent Application Containing Nucleotide and/or Amino Acid Sequence Disclosures (2 pages)

Petition for One Month Extension of Time Under 37 CFR 1.136(a) (1 page)

Transmittal of POA (1 page) Power of Attorney (1 page)

Statement Under 37 CFR 3.73(b) (1 page)

Copy of Assignment and Recordation Cover Sheet (3 pages)

Postcard

Note:

Charge \$120.00 to deposit account 03-2775

10/519210

PTO/SB/22 (12-04)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

01/31/2006 PKIDWELL 00000006 032775

120.00 DA

01 FC:1251

10519210

Under the Paperwork F	Reduction Act of 1995, no persons are require	d to respond to a collection	of information unles	s if displays a valid Ol	MB control number.	
PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2005			Docket Number (Optional)			
(Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)			'			
Application Number	10/519210		Filed	December 23	2004	
For PLASMID VI	ECTORS FOR TRANSFORMATI	ON OF FILAMENT	OUS FUNGI			
Art Unit Not Y	Art Unit Not Yet Assigned		Examiner Not Yet Assigned			
identified application	nder the provisions of 37 CFR 1.15 n. n. nsion and fee are as follows (che					
		Fee	Small Entity	/ Fee		
X One mo	onth (37 CFR 1.17(a)(1))	\$120	\$60		120.00	
Two mo	onths (37 CFR 1.17(a)(2))	\$450	\$225	\$		
Three r	months (37 CFR 1.17(a)(3))	\$1020	\$510	\$		
Four m	onths (37 CFR 1.17(a)(4))	\$1590	\$795	\$		
Five mo	onths (37 CFR 1.17(a)(5))	\$2160	\$1080	\$	120.00	
Applicant cla	nims small entity status See 37 (CER 1 27				
Applicant claims small entity status. See 37 CFR 1.27. A check in the amount of the fee is enclosed.						
\vdash	credit card. Form PTO-2038 is a					
	has already been authorized to o		annlication to a	Denosit Accoun	.	
	· · · · · · · · · · · · · · · · · · ·					
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 03-2775 . I have enclosed a duplicate copy of this sheet.						
				.,	ĺ	
I am the	applicant/inventor.				1	
	assignee of record of the entire Statement under 37 CFR			B/96).		
	attorney or agent of record. R	Registration Number	·			
x	attorney or agent under 37 CF	FR 1.34.				
	Registration number if acting un		55,42	21 .		
- Kolon	te plapouski		Se	ptember 21, 200)5	
	Signature			Date		
	Roberte M. D. Makowski, Ph.D.			(302) 658-9141	<u> </u>	
•	Typed or printed name		16	elephone Numbe	; ı	

416656

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

forms are submitted.